Table 11All-Cause and Pulmonary Arterial Hypertension–Related Deaths

Analyses of DeathsGRIPHON Study
Selexipag
N = 574		Placebo
N = 582		HR (99% CI)
All deaths up to study closurea100 (17.4)105 (18.0)0.97 (0.68 to 1.39)
Deaths due to PAH up to study closurea70 (12.2)83 (14.3)0.86 (0.63 to 1.18)
All deaths up to EOT + 7 days46 (8.0)37 (6.4)1.17 (0.66 to 2.07)6
All deaths up to EOT + 30 days▬▬▬

CI = confidence interval; EOT = end of treatment; HR = hazard ratio; PAH = pulmonary arterial hypertension.

a

The median follow-up times for all deaths to study closure was selexipag 98.3 weeks and placebo 98.0 weeks.6

Note: These data are from the full analysis set.

Source: Clinical Study Report;8 additional information from the manufacturer.6

From: 3, Results

Cover of Clinical Review Report: Slexipag (Uptravi)
Clinical Review Report: Slexipag (Uptravi) [Internet].
Copyright © 2017 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.